同花顺美股讯 4月8日Keybanc将哈佛生物科学评级从增持下调评级为板块表现。哈佛生物科学于3月14日发布2024年年报,公司截至2024年12月31日,营业收入9413.50万美元,同比-16.14%,净利润-1240.50万美元,基本每股收益-0.28美元。Harvard Bioscience, Inc.于1901年成立注册于特拉华州。该公司是技术、产品和服务的领先开发商、制造商和销售商,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.